Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Elion

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
AIDS Reviews|February 11, 2005
Considerations in selecting protease inhibitor therapyBrian A Boyle, Richard A Elion, Graeme J Moyle, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|August 29, 2003
Once-daily antiretroviral therapies for HIV infection: Consensus Statement of an Advisory Committee of the International Association of Physicians in AIDS CareCalvin Cohen, Richard A Elion, Ian Frank, et al.
International Journal of Environmental Research and Public Health|May 10, 2019
Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United StatesRichard A Elion, Mina Kabiri, Kenneth H Mayer, et al.
AIDS Research and Therapy|September 27, 2025
Clinical outcomes on B/F/TAF and dolutegravir-based regimens at 12 months following regimen switch: an observational cohort studyPaul E Sax, Janna Radtchenko, Megan Dunbar, et al.
AIDS (London, England)|March 7, 2025
Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruptionGraeme Moyle, Joshua Gruber, Megan Dunbar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 14, 2019
Brief Report: Durability of the Effect of Financial Incentives on HIV Viral Load Suppression and Continuity in Care: HPTN 065 StudyWafaa M El-Sadr, Geetha Beauchamp, H Irene Hall, et al.
Plos One|February 14, 2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCVSonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, et al.
AIDS Patient Care and Stds|June 5, 2026
People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and OutcomesPaul E Sax, Keith J Dunn, Janna Radtchenko, et al.
AIDS Patient Care and Stds|March 26, 2014
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysisGeorg Behrens, Bart Rijnders, Mark Nelson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 2, 2022
Statins Utilization in Adults With HIV: The Treatment Gap and Predictors of Statin InitiationSally B Coburn, Raynell Lang, Jinbing Zhang, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
AIDS Reviews|February 11, 2005
Considerations in selecting protease inhibitor therapyBrian A Boyle, Richard A Elion, Graeme J Moyle, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|August 29, 2003
Once-daily antiretroviral therapies for HIV infection: Consensus Statement of an Advisory Committee of the International Association of Physicians in AIDS CareCalvin Cohen, Richard A Elion, Ian Frank, et al.
International Journal of Environmental Research and Public Health|May 10, 2019
Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United StatesRichard A Elion, Mina Kabiri, Kenneth H Mayer, et al.
AIDS Research and Therapy|September 27, 2025
Clinical outcomes on B/F/TAF and dolutegravir-based regimens at 12 months following regimen switch: an observational cohort studyPaul E Sax, Janna Radtchenko, Megan Dunbar, et al.
AIDS (London, England)|March 7, 2025
Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruptionGraeme Moyle, Joshua Gruber, Megan Dunbar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 14, 2019
Brief Report: Durability of the Effect of Financial Incentives on HIV Viral Load Suppression and Continuity in Care: HPTN 065 StudyWafaa M El-Sadr, Geetha Beauchamp, H Irene Hall, et al.
Plos One|February 14, 2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCVSonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, et al.
AIDS Patient Care and Stds|June 5, 2026
People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and OutcomesPaul E Sax, Keith J Dunn, Janna Radtchenko, et al.
AIDS Patient Care and Stds|March 26, 2014
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysisGeorg Behrens, Bart Rijnders, Mark Nelson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 2, 2022
Statins Utilization in Adults With HIV: The Treatment Gap and Predictors of Statin InitiationSally B Coburn, Raynell Lang, Jinbing Zhang, et al.
Pageof 2